SAN FRANCISCO — One of the U.S. biotech industry’s preferred partners in China, Jiangsu Hengrui Pharmaceuticals, emphasized its global ambitions and plans for more dealmaking at
Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a common type of heart failure? How will we know if
Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting
Have you ever seen a mouse with a set of muscles more appropriate for a bodybuilder or comic book superhero? Well, 25 years ago, researchers
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying
Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled